Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | STAT1 | P42224 | 1/20 | 0.59 |
| ▸ | RHOA | P61586 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.57 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493878 | 1.00 | DEGS1 (0.60) | DEGS1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27605647 | 0.81 | DEGS1 (0.58) | DEGS1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL31489320 | 0.79 | KDM4E (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1RHOA | |
| SCHEMBL13134249 | 0.79 | KDM4E (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1RHOA | |
| SCHEMBL16101601 | 0.78 | KDR (0.60) | DEGS1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13991500 | 0.78 | KDR (0.60) | DEGS1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27960240 | 0.77 | RHOA (0.79) | RAB9ANPC1RHOAHDAC3HDAC4 | |
| SCHEMBL16102104 | 0.76 | SMN1; SMN2 (0.53) | DEGS1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20284449 | 0.75 | DEGS1 (1.00) | DEGS1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29186499 | 0.75 | KDM4E (0.68) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20040235888-A1 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | APOL1, PON1, APOB | DEGS1 998/4885RAB9A 4068/4885NPC1 226/4885 |
| US-20040235888-A1 | Utilities of amide compounds | APOB, NR1H2, APOL1 | DEGS1 620/4885RAB9A 4044/4885NPC1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.